recombinant mouse ldlr associated protein Search Results


90
EIAab Inc recombinant mouse hsp20 protein
(A) The serum <t>Hsp20</t> level was increased in response to in vivo 30 min-LAD occlusion followed by 24 h-reperfusion. Cardiac-specific overexpression of Hsp20 increased the Hsp20 concentration in the serum under basal and myocardial ischemia/reperfusion conditions. (n = 6; *, p<0.05 vs. WTs; #, p<0.05 vs. Sham groups). (B) The levels of Hsp20 in hearts from Hsp20-transgenic mice were determined by Western blot. α-Actin was used as an internal control (n = 4). (C) Myocardial ischemia/reperfusion stimulated the translocation of Hsp20 to the cardiomyocyte membrane, which was detected by fluorescence microscopy. Images are representative sections from four mice per group (green, Hsp20; red, α-Actin; Scale bar, 100 µm). (D) Quantitative data for expression of Hsp20 was evaluated using IPP 5.1 (n = 4; *, p<0.05 vs. WTs; #, p<0.05 vs. Sham groups).
Recombinant Mouse Hsp20 Protein, supplied by EIAab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ldlr+associated+protein/pmc03299679-39-2-6?v=EIAab+Inc
Average 90 stars, based on 1 article reviews
recombinant mouse hsp20 protein - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
ATGen Inc recombinant mouse gad antibody
(A) The serum <t>Hsp20</t> level was increased in response to in vivo 30 min-LAD occlusion followed by 24 h-reperfusion. Cardiac-specific overexpression of Hsp20 increased the Hsp20 concentration in the serum under basal and myocardial ischemia/reperfusion conditions. (n = 6; *, p<0.05 vs. WTs; #, p<0.05 vs. Sham groups). (B) The levels of Hsp20 in hearts from Hsp20-transgenic mice were determined by Western blot. α-Actin was used as an internal control (n = 4). (C) Myocardial ischemia/reperfusion stimulated the translocation of Hsp20 to the cardiomyocyte membrane, which was detected by fluorescence microscopy. Images are representative sections from four mice per group (green, Hsp20; red, α-Actin; Scale bar, 100 µm). (D) Quantitative data for expression of Hsp20 was evaluated using IPP 5.1 (n = 4; *, p<0.05 vs. WTs; #, p<0.05 vs. Sham groups).
Recombinant Mouse Gad Antibody, supplied by ATGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ldlr+associated+protein/pmc03195669-27-0-22?v=ATGen+Inc
Average 90 stars, based on 1 article reviews
recombinant mouse gad antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Metamorphix inc recombinant mouse myostatin
(A) The serum <t>Hsp20</t> level was increased in response to in vivo 30 min-LAD occlusion followed by 24 h-reperfusion. Cardiac-specific overexpression of Hsp20 increased the Hsp20 concentration in the serum under basal and myocardial ischemia/reperfusion conditions. (n = 6; *, p<0.05 vs. WTs; #, p<0.05 vs. Sham groups). (B) The levels of Hsp20 in hearts from Hsp20-transgenic mice were determined by Western blot. α-Actin was used as an internal control (n = 4). (C) Myocardial ischemia/reperfusion stimulated the translocation of Hsp20 to the cardiomyocyte membrane, which was detected by fluorescence microscopy. Images are representative sections from four mice per group (green, Hsp20; red, α-Actin; Scale bar, 100 µm). (D) Quantitative data for expression of Hsp20 was evaluated using IPP 5.1 (n = 4; *, p<0.05 vs. WTs; #, p<0.05 vs. Sham groups).
Recombinant Mouse Myostatin, supplied by Metamorphix inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ldlr+associated+protein/pmc02528853-262-1-4?v=Metamorphix+inc
Average 90 stars, based on 1 article reviews
recombinant mouse myostatin - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Lonza recombinant mouse tsg-6
(A) The serum <t>Hsp20</t> level was increased in response to in vivo 30 min-LAD occlusion followed by 24 h-reperfusion. Cardiac-specific overexpression of Hsp20 increased the Hsp20 concentration in the serum under basal and myocardial ischemia/reperfusion conditions. (n = 6; *, p<0.05 vs. WTs; #, p<0.05 vs. Sham groups). (B) The levels of Hsp20 in hearts from Hsp20-transgenic mice were determined by Western blot. α-Actin was used as an internal control (n = 4). (C) Myocardial ischemia/reperfusion stimulated the translocation of Hsp20 to the cardiomyocyte membrane, which was detected by fluorescence microscopy. Images are representative sections from four mice per group (green, Hsp20; red, α-Actin; Scale bar, 100 µm). (D) Quantitative data for expression of Hsp20 was evaluated using IPP 5.1 (n = 4; *, p<0.05 vs. WTs; #, p<0.05 vs. Sham groups).
Recombinant Mouse Tsg 6, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ldlr+associated+protein/pmc01867074-37-0-10?v=Lonza
Average 90 stars, based on 1 article reviews
recombinant mouse tsg-6 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

97
R&D Systems mouse tnf α duoset elisa kit
PLY-EVs induce dendritic cell maturation and inflammatory cytokine release upon internalization (A) Confocal microscopy images showing the internalization of CFSE-labelled PLY (0.1) and naive EVs (green) by THP-1-monocyte-derived DCs at 24 h post-treatment. Scale bars, 25 μm. (B) Flow cytometry histograms ( N = 3) to quantify the DC uptake of CFSE-labeled PLY(0.5)EVs and naive EVs. (C) Dose-dependent uptake of PLY (0.1, 0.5) EVs by DCs. (D) Phase-contrast microscopy images of immature day 5 DCs coincubated with PLY (0.1, 0.5) EVs and naive EVs for 24 h. Arrows indicate matured DCs (magnified in inset). Scale bars, 50 μm. Images are representative of three independent experiments. (E–G) Flow cytometry histograms ( N = 3) to quantify the expression levels of (E) CD80, (F) CD86, and (G) CD83 on THP-1-monocyte-derived DCs treated with PLY(0.5) and naive EVs. (H and I) Flow cytometry histograms ( N = 2) showing the expression levels of DC maturation marker CD83 at 96 h post-incubation of primary human monocytes with (H) PLY(0.5) and naive EVs and (I) naive EVs pre-treated with recombinant PLY protein (naive EVs+rPLY). (J and K) Cytokine <t>ELISA</t> showing the levels of secreted TNF-α from (J) DCs treated with PLY (0.1) EVs or naive EVs alone ( N = 3) for 24 h and (K) DCs pre-treated with PLY (0.1,0.5) or naive EVs for 24 h followed by subsequent infection with S. pneumoniae , T4R strain ( N = 2). Recombinant PLY (0.5 μg/mL) was used as positive control. All data are represented as mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.005, and ∗∗∗ p < 0.001 by one-way ANOVA with Tukey’s multiple comparisons test. n.s., not significant. See also <xref ref-type=Figures S6–S9 . " width="250" height="auto" />
Mouse Tnf α Duoset Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ldlr+associated+protein/pmc11357855-101-0-6?v=R%26D+Systems
Average 97 stars, based on 1 article reviews
mouse tnf α duoset elisa kit - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology concanamycin a santa cruz biotechnology sc
PLY-EVs induce dendritic cell maturation and inflammatory cytokine release upon internalization (A) Confocal microscopy images showing the internalization of CFSE-labelled PLY (0.1) and naive EVs (green) by THP-1-monocyte-derived DCs at 24 h post-treatment. Scale bars, 25 μm. (B) Flow cytometry histograms ( N = 3) to quantify the DC uptake of CFSE-labeled PLY(0.5)EVs and naive EVs. (C) Dose-dependent uptake of PLY (0.1, 0.5) EVs by DCs. (D) Phase-contrast microscopy images of immature day 5 DCs coincubated with PLY (0.1, 0.5) EVs and naive EVs for 24 h. Arrows indicate matured DCs (magnified in inset). Scale bars, 50 μm. Images are representative of three independent experiments. (E–G) Flow cytometry histograms ( N = 3) to quantify the expression levels of (E) CD80, (F) CD86, and (G) CD83 on THP-1-monocyte-derived DCs treated with PLY(0.5) and naive EVs. (H and I) Flow cytometry histograms ( N = 2) showing the expression levels of DC maturation marker CD83 at 96 h post-incubation of primary human monocytes with (H) PLY(0.5) and naive EVs and (I) naive EVs pre-treated with recombinant PLY protein (naive EVs+rPLY). (J and K) Cytokine <t>ELISA</t> showing the levels of secreted TNF-α from (J) DCs treated with PLY (0.1) EVs or naive EVs alone ( N = 3) for 24 h and (K) DCs pre-treated with PLY (0.1,0.5) or naive EVs for 24 h followed by subsequent infection with S. pneumoniae , T4R strain ( N = 2). Recombinant PLY (0.5 μg/mL) was used as positive control. All data are represented as mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.005, and ∗∗∗ p < 0.001 by one-way ANOVA with Tukey’s multiple comparisons test. n.s., not significant. See also <xref ref-type=Figures S6–S9 . " width="250" height="auto" />
Concanamycin A Santa Cruz Biotechnology Sc, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ldlr+associated+protein/pm37699397-870-132-134?v=Santa+Cruz+Biotechnology
Average 94 stars, based on 1 article reviews
concanamycin a santa cruz biotechnology sc - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

93
R&D Systems caspase 1 inhibitor ac yvad cmk
PLY-EVs induce dendritic cell maturation and inflammatory cytokine release upon internalization (A) Confocal microscopy images showing the internalization of CFSE-labelled PLY (0.1) and naive EVs (green) by THP-1-monocyte-derived DCs at 24 h post-treatment. Scale bars, 25 μm. (B) Flow cytometry histograms ( N = 3) to quantify the DC uptake of CFSE-labeled PLY(0.5)EVs and naive EVs. (C) Dose-dependent uptake of PLY (0.1, 0.5) EVs by DCs. (D) Phase-contrast microscopy images of immature day 5 DCs coincubated with PLY (0.1, 0.5) EVs and naive EVs for 24 h. Arrows indicate matured DCs (magnified in inset). Scale bars, 50 μm. Images are representative of three independent experiments. (E–G) Flow cytometry histograms ( N = 3) to quantify the expression levels of (E) CD80, (F) CD86, and (G) CD83 on THP-1-monocyte-derived DCs treated with PLY(0.5) and naive EVs. (H and I) Flow cytometry histograms ( N = 2) showing the expression levels of DC maturation marker CD83 at 96 h post-incubation of primary human monocytes with (H) PLY(0.5) and naive EVs and (I) naive EVs pre-treated with recombinant PLY protein (naive EVs+rPLY). (J and K) Cytokine <t>ELISA</t> showing the levels of secreted TNF-α from (J) DCs treated with PLY (0.1) EVs or naive EVs alone ( N = 3) for 24 h and (K) DCs pre-treated with PLY (0.1,0.5) or naive EVs for 24 h followed by subsequent infection with S. pneumoniae , T4R strain ( N = 2). Recombinant PLY (0.5 μg/mL) was used as positive control. All data are represented as mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.005, and ∗∗∗ p < 0.001 by one-way ANOVA with Tukey’s multiple comparisons test. n.s., not significant. See also <xref ref-type=Figures S6–S9 . " width="250" height="auto" />
Caspase 1 Inhibitor Ac Yvad Cmk, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ldlr+associated+protein/pm19717513-66-12-30?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
caspase 1 inhibitor ac yvad cmk - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

95
Selleck Chemicals s1413 pepstatin a selleck
PLY-EVs induce dendritic cell maturation and inflammatory cytokine release upon internalization (A) Confocal microscopy images showing the internalization of CFSE-labelled PLY (0.1) and naive EVs (green) by THP-1-monocyte-derived DCs at 24 h post-treatment. Scale bars, 25 μm. (B) Flow cytometry histograms ( N = 3) to quantify the DC uptake of CFSE-labeled PLY(0.5)EVs and naive EVs. (C) Dose-dependent uptake of PLY (0.1, 0.5) EVs by DCs. (D) Phase-contrast microscopy images of immature day 5 DCs coincubated with PLY (0.1, 0.5) EVs and naive EVs for 24 h. Arrows indicate matured DCs (magnified in inset). Scale bars, 50 μm. Images are representative of three independent experiments. (E–G) Flow cytometry histograms ( N = 3) to quantify the expression levels of (E) CD80, (F) CD86, and (G) CD83 on THP-1-monocyte-derived DCs treated with PLY(0.5) and naive EVs. (H and I) Flow cytometry histograms ( N = 2) showing the expression levels of DC maturation marker CD83 at 96 h post-incubation of primary human monocytes with (H) PLY(0.5) and naive EVs and (I) naive EVs pre-treated with recombinant PLY protein (naive EVs+rPLY). (J and K) Cytokine <t>ELISA</t> showing the levels of secreted TNF-α from (J) DCs treated with PLY (0.1) EVs or naive EVs alone ( N = 3) for 24 h and (K) DCs pre-treated with PLY (0.1,0.5) or naive EVs for 24 h followed by subsequent infection with S. pneumoniae , T4R strain ( N = 2). Recombinant PLY (0.5 μg/mL) was used as positive control. All data are represented as mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.005, and ∗∗∗ p < 0.001 by one-way ANOVA with Tukey’s multiple comparisons test. n.s., not significant. See also <xref ref-type=Figures S6–S9 . " width="250" height="auto" />
S1413 Pepstatin A Selleck, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ldlr+associated+protein/pm41483803-240-30-33?v=Selleck+Chemicals
Average 95 stars, based on 1 article reviews
s1413 pepstatin a selleck - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

94
Selleck Chemicals mb ms275 selleck
PLY-EVs induce dendritic cell maturation and inflammatory cytokine release upon internalization (A) Confocal microscopy images showing the internalization of CFSE-labelled PLY (0.1) and naive EVs (green) by THP-1-monocyte-derived DCs at 24 h post-treatment. Scale bars, 25 μm. (B) Flow cytometry histograms ( N = 3) to quantify the DC uptake of CFSE-labeled PLY(0.5)EVs and naive EVs. (C) Dose-dependent uptake of PLY (0.1, 0.5) EVs by DCs. (D) Phase-contrast microscopy images of immature day 5 DCs coincubated with PLY (0.1, 0.5) EVs and naive EVs for 24 h. Arrows indicate matured DCs (magnified in inset). Scale bars, 50 μm. Images are representative of three independent experiments. (E–G) Flow cytometry histograms ( N = 3) to quantify the expression levels of (E) CD80, (F) CD86, and (G) CD83 on THP-1-monocyte-derived DCs treated with PLY(0.5) and naive EVs. (H and I) Flow cytometry histograms ( N = 2) showing the expression levels of DC maturation marker CD83 at 96 h post-incubation of primary human monocytes with (H) PLY(0.5) and naive EVs and (I) naive EVs pre-treated with recombinant PLY protein (naive EVs+rPLY). (J and K) Cytokine <t>ELISA</t> showing the levels of secreted TNF-α from (J) DCs treated with PLY (0.1) EVs or naive EVs alone ( N = 3) for 24 h and (K) DCs pre-treated with PLY (0.1,0.5) or naive EVs for 24 h followed by subsequent infection with S. pneumoniae , T4R strain ( N = 2). Recombinant PLY (0.5 μg/mL) was used as positive control. All data are represented as mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.005, and ∗∗∗ p < 0.001 by one-way ANOVA with Tukey’s multiple comparisons test. n.s., not significant. See also <xref ref-type=Figures S6–S9 . " width="250" height="auto" />
Mb Ms275 Selleck, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ldlr+associated+protein/pm35081346-200-69-71?v=Selleck+Chemicals
Average 94 stars, based on 1 article reviews
mb ms275 selleck - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

94
Selleck Chemicals pdtc ammonium
κ ( A ) Immunoblotting of A20 and NF-κB p65 in whole-cell extract from B cell lymphoma cell lines. ( B ) Immunoblotting of NF-κB p65 in cytosolic and nuclear fractions of indicated cell lines. TBP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as loading controls. ( C ) Quantification of mean (±SD) TNF secretion by indicated cell lines ( n = 3 to 4 biological replicates). ( D ) Mean (±SD) proliferation and ( E ) viability of indicated cell lines ( n = 6 biological replicates) after 72 hours of incubation with anti-TNF antibody infliximab or human IgG (Intratect). Dotted lines represent seeded cell number. ( F ) Immunoblotting of A20 and NF-κB p65 after lentiviral transduction of A20 in RI-1 cells. ( G ) Immunoblotting of NF-κB p65 in cytosolic and nuclear fractions after A20 reconstitution in RI-1 cells. ( H ) Mean (±SD) TNF secretion after lentiviral transduction of A20 in RI-1 cells ( n = 3 biological replicates). ( I ) Mean (±SD) proliferation of A20-overexpressing RI-1 cells in the presence of infliximab ( n = 4 biological replicates). Statistics: one-way ANOVA. ( J ) Volcano plot showing differential gene expression between RI-1 wt and RI-1 + pLeGO-A20 as determined by RNA-seq performed in duplicates. Genes were considered differentially expressed with an adjust P < 0.01 and log 2 fold change >1. ( K ) Top down-regulated signaling pathways in RI-1 + pLeGO-A20 cells. All adjusted P values <0.0001. ( L ) Immunoblotting of NF-κB p65 in whole-cell extract and quantification of secreted TNF after incubation with 100 μM <t>PDTC</t> for 1 hour ( n = 3 biological replicates). ( M ) Quantification of mean (±SD) TNF secretion after stimulation with 100 <t>ng/ml</t> <t>recombinant</t> TNF for 1 hour ( n = 3 biological replicates). * P < 0.05; ** P < 0.01.
Pdtc Ammonium, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ldlr+associated+protein/pmc11338232-210-21-23?v=Selleck+Chemicals
Average 94 stars, based on 1 article reviews
pdtc ammonium - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

95
Selleck Chemicals c646 selleck cat
κ ( A ) Immunoblotting of A20 and NF-κB p65 in whole-cell extract from B cell lymphoma cell lines. ( B ) Immunoblotting of NF-κB p65 in cytosolic and nuclear fractions of indicated cell lines. TBP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as loading controls. ( C ) Quantification of mean (±SD) TNF secretion by indicated cell lines ( n = 3 to 4 biological replicates). ( D ) Mean (±SD) proliferation and ( E ) viability of indicated cell lines ( n = 6 biological replicates) after 72 hours of incubation with anti-TNF antibody infliximab or human IgG (Intratect). Dotted lines represent seeded cell number. ( F ) Immunoblotting of A20 and NF-κB p65 after lentiviral transduction of A20 in RI-1 cells. ( G ) Immunoblotting of NF-κB p65 in cytosolic and nuclear fractions after A20 reconstitution in RI-1 cells. ( H ) Mean (±SD) TNF secretion after lentiviral transduction of A20 in RI-1 cells ( n = 3 biological replicates). ( I ) Mean (±SD) proliferation of A20-overexpressing RI-1 cells in the presence of infliximab ( n = 4 biological replicates). Statistics: one-way ANOVA. ( J ) Volcano plot showing differential gene expression between RI-1 wt and RI-1 + pLeGO-A20 as determined by RNA-seq performed in duplicates. Genes were considered differentially expressed with an adjust P < 0.01 and log 2 fold change >1. ( K ) Top down-regulated signaling pathways in RI-1 + pLeGO-A20 cells. All adjusted P values <0.0001. ( L ) Immunoblotting of NF-κB p65 in whole-cell extract and quantification of secreted TNF after incubation with 100 μM <t>PDTC</t> for 1 hour ( n = 3 biological replicates). ( M ) Quantification of mean (±SD) TNF secretion after stimulation with 100 <t>ng/ml</t> <t>recombinant</t> TNF for 1 hour ( n = 3 biological replicates). * P < 0.05; ** P < 0.01.
C646 Selleck Cat, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ldlr+associated+protein/pm28844862-227-70-71?v=Selleck+Chemicals
Average 95 stars, based on 1 article reviews
c646 selleck cat - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

90
Sino Biological rat pcsk9
κ ( A ) Immunoblotting of A20 and NF-κB p65 in whole-cell extract from B cell lymphoma cell lines. ( B ) Immunoblotting of NF-κB p65 in cytosolic and nuclear fractions of indicated cell lines. TBP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as loading controls. ( C ) Quantification of mean (±SD) TNF secretion by indicated cell lines ( n = 3 to 4 biological replicates). ( D ) Mean (±SD) proliferation and ( E ) viability of indicated cell lines ( n = 6 biological replicates) after 72 hours of incubation with anti-TNF antibody infliximab or human IgG (Intratect). Dotted lines represent seeded cell number. ( F ) Immunoblotting of A20 and NF-κB p65 after lentiviral transduction of A20 in RI-1 cells. ( G ) Immunoblotting of NF-κB p65 in cytosolic and nuclear fractions after A20 reconstitution in RI-1 cells. ( H ) Mean (±SD) TNF secretion after lentiviral transduction of A20 in RI-1 cells ( n = 3 biological replicates). ( I ) Mean (±SD) proliferation of A20-overexpressing RI-1 cells in the presence of infliximab ( n = 4 biological replicates). Statistics: one-way ANOVA. ( J ) Volcano plot showing differential gene expression between RI-1 wt and RI-1 + pLeGO-A20 as determined by RNA-seq performed in duplicates. Genes were considered differentially expressed with an adjust P < 0.01 and log 2 fold change >1. ( K ) Top down-regulated signaling pathways in RI-1 + pLeGO-A20 cells. All adjusted P values <0.0001. ( L ) Immunoblotting of NF-κB p65 in whole-cell extract and quantification of secreted TNF after incubation with 100 μM <t>PDTC</t> for 1 hour ( n = 3 biological replicates). ( M ) Quantification of mean (±SD) TNF secretion after stimulation with 100 <t>ng/ml</t> <t>recombinant</t> TNF for 1 hour ( n = 3 biological replicates). * P < 0.05; ** P < 0.01.
Rat Pcsk9, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ldlr+associated+protein/us10077319-1095-9-11?v=Sino+Biological
Average 90 stars, based on 1 article reviews
rat pcsk9 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


(A) The serum Hsp20 level was increased in response to in vivo 30 min-LAD occlusion followed by 24 h-reperfusion. Cardiac-specific overexpression of Hsp20 increased the Hsp20 concentration in the serum under basal and myocardial ischemia/reperfusion conditions. (n = 6; *, p<0.05 vs. WTs; #, p<0.05 vs. Sham groups). (B) The levels of Hsp20 in hearts from Hsp20-transgenic mice were determined by Western blot. α-Actin was used as an internal control (n = 4). (C) Myocardial ischemia/reperfusion stimulated the translocation of Hsp20 to the cardiomyocyte membrane, which was detected by fluorescence microscopy. Images are representative sections from four mice per group (green, Hsp20; red, α-Actin; Scale bar, 100 µm). (D) Quantitative data for expression of Hsp20 was evaluated using IPP 5.1 (n = 4; *, p<0.05 vs. WTs; #, p<0.05 vs. Sham groups).

Journal: PLoS ONE

Article Title: Hsp20 Functions as a Novel Cardiokine in Promoting Angiogenesis via Activation of VEGFR2

doi: 10.1371/journal.pone.0032765

Figure Lengend Snippet: (A) The serum Hsp20 level was increased in response to in vivo 30 min-LAD occlusion followed by 24 h-reperfusion. Cardiac-specific overexpression of Hsp20 increased the Hsp20 concentration in the serum under basal and myocardial ischemia/reperfusion conditions. (n = 6; *, p<0.05 vs. WTs; #, p<0.05 vs. Sham groups). (B) The levels of Hsp20 in hearts from Hsp20-transgenic mice were determined by Western blot. α-Actin was used as an internal control (n = 4). (C) Myocardial ischemia/reperfusion stimulated the translocation of Hsp20 to the cardiomyocyte membrane, which was detected by fluorescence microscopy. Images are representative sections from four mice per group (green, Hsp20; red, α-Actin; Scale bar, 100 µm). (D) Quantitative data for expression of Hsp20 was evaluated using IPP 5.1 (n = 4; *, p<0.05 vs. WTs; #, p<0.05 vs. Sham groups).

Article Snippet: Samples or recombinant mouse Hsp20 protein (EIAab Science) were added and incubated for 2 h followed by three washes in PBST.

Techniques: In Vivo, Over Expression, Concentration Assay, Transgenic Assay, Western Blot, Control, Translocation Assay, Membrane, Fluorescence, Microscopy, Expressing

(A) Mild stress dose-dependently increased the amount of Hsp20 released from both Ad.GFP and Ad.Hsp20 infected myocytes, and (B) there was no difference in the release of lactate dehydrogenase (LDH), a marker of necrosis. Similar results were observed in two additional, independent experiments (*, p<0.05 vs. Ad.GFP-Control; #, p<0.05 vs. Ad.GFP).

Journal: PLoS ONE

Article Title: Hsp20 Functions as a Novel Cardiokine in Promoting Angiogenesis via Activation of VEGFR2

doi: 10.1371/journal.pone.0032765

Figure Lengend Snippet: (A) Mild stress dose-dependently increased the amount of Hsp20 released from both Ad.GFP and Ad.Hsp20 infected myocytes, and (B) there was no difference in the release of lactate dehydrogenase (LDH), a marker of necrosis. Similar results were observed in two additional, independent experiments (*, p<0.05 vs. Ad.GFP-Control; #, p<0.05 vs. Ad.GFP).

Article Snippet: Samples or recombinant mouse Hsp20 protein (EIAab Science) were added and incubated for 2 h followed by three washes in PBST.

Techniques: Infection, Marker, Control

(A) Brefeldin A (BFA), which inhibits the classical protein transport pathway, did not block Hsp20 release into the media under either basal or hypoxia conditions (20 µM H 2 O 2 ). However, the release of Hsp20 from cardiomyocytes was reduced by both dimethyl amiloride (DMA), an exosome inhibitor, and Methyl-β-cyclodextrin (MBC), an inhibitor of lipid raft formation via depletion of membrane cholesterol. (B) The activity of acetylcholine esterase was used to quantify the amount of exosomes present in the media after various treatments. Similar results were observed in three additional, independent experiments (*, p<0.05 vs. Basal-Control; #, p<0.05 vs. H 2 O 2 -Control).

Journal: PLoS ONE

Article Title: Hsp20 Functions as a Novel Cardiokine in Promoting Angiogenesis via Activation of VEGFR2

doi: 10.1371/journal.pone.0032765

Figure Lengend Snippet: (A) Brefeldin A (BFA), which inhibits the classical protein transport pathway, did not block Hsp20 release into the media under either basal or hypoxia conditions (20 µM H 2 O 2 ). However, the release of Hsp20 from cardiomyocytes was reduced by both dimethyl amiloride (DMA), an exosome inhibitor, and Methyl-β-cyclodextrin (MBC), an inhibitor of lipid raft formation via depletion of membrane cholesterol. (B) The activity of acetylcholine esterase was used to quantify the amount of exosomes present in the media after various treatments. Similar results were observed in three additional, independent experiments (*, p<0.05 vs. Basal-Control; #, p<0.05 vs. H 2 O 2 -Control).

Article Snippet: Samples or recombinant mouse Hsp20 protein (EIAab Science) were added and incubated for 2 h followed by three washes in PBST.

Techniques: Blocking Assay, Membrane, Activity Assay, Control

(A) Recombinant human Hsp20 protein was added to HUVECs at various doses (80–2000 ng/ml) for 24 h. BSA was used as a control. Cell proliferation was determined by MTS. (B) Time-course effects of the Hsp20 protein(1000 ng/ml) on the HUVEC proliferation. (C) Representative photographs indicated the effects of recombinant human Hsp20 protein on the trans-well and tube formation of HUVECs. (D) Migration was quantified by counting cells that were moved through the membrane (Trans-well assay). (E) Tube formation was evaluated by the measurement of relative tube length. Similar results were observed in three additional, independent experiments (*, p<0.05 vs. Control).

Journal: PLoS ONE

Article Title: Hsp20 Functions as a Novel Cardiokine in Promoting Angiogenesis via Activation of VEGFR2

doi: 10.1371/journal.pone.0032765

Figure Lengend Snippet: (A) Recombinant human Hsp20 protein was added to HUVECs at various doses (80–2000 ng/ml) for 24 h. BSA was used as a control. Cell proliferation was determined by MTS. (B) Time-course effects of the Hsp20 protein(1000 ng/ml) on the HUVEC proliferation. (C) Representative photographs indicated the effects of recombinant human Hsp20 protein on the trans-well and tube formation of HUVECs. (D) Migration was quantified by counting cells that were moved through the membrane (Trans-well assay). (E) Tube formation was evaluated by the measurement of relative tube length. Similar results were observed in three additional, independent experiments (*, p<0.05 vs. Control).

Article Snippet: Samples or recombinant mouse Hsp20 protein (EIAab Science) were added and incubated for 2 h followed by three washes in PBST.

Techniques: Recombinant, Control, Migration, Membrane

(A) VEGFR2 coated on a plate dose-dependently captured the Hsp20 protein, whereas BSA coated did not arrest the Hsp20 protein. (B) Recombinant human Hsp20 protein significantly induced the expression of VRGFR2 in HUVECs, and co-localized with VEGFR2 in the cell surface. Images are representative sections from 20 fields per group (green, Hsp20; red, VEGFR2). Scale bar, 25 µm. (C–E) Blockade of the VEGFR2 signaling by a VEGFR2 neutralizing antibody and CBO-P11 (a VEGFR inhibitor) suppressed the HUVEC migration (C and D) and tube formation (C and E). Similar results were observed in three additional, independent experiments (*, p<0.05 vs. Control). (F and G) Immunoblots determined the levels of Akt, p-Akt, ERK and p-ERK in Hsp20-treated HUVECs. IgG or VEGFR2 antibody was pre-treated 30 min prior to the addition of Hsp20. β-actin was used as an internal control (n = 4; *, p<0.05 vs. Basal; #, p<0.05 vs. IgG+Hsp20).

Journal: PLoS ONE

Article Title: Hsp20 Functions as a Novel Cardiokine in Promoting Angiogenesis via Activation of VEGFR2

doi: 10.1371/journal.pone.0032765

Figure Lengend Snippet: (A) VEGFR2 coated on a plate dose-dependently captured the Hsp20 protein, whereas BSA coated did not arrest the Hsp20 protein. (B) Recombinant human Hsp20 protein significantly induced the expression of VRGFR2 in HUVECs, and co-localized with VEGFR2 in the cell surface. Images are representative sections from 20 fields per group (green, Hsp20; red, VEGFR2). Scale bar, 25 µm. (C–E) Blockade of the VEGFR2 signaling by a VEGFR2 neutralizing antibody and CBO-P11 (a VEGFR inhibitor) suppressed the HUVEC migration (C and D) and tube formation (C and E). Similar results were observed in three additional, independent experiments (*, p<0.05 vs. Control). (F and G) Immunoblots determined the levels of Akt, p-Akt, ERK and p-ERK in Hsp20-treated HUVECs. IgG or VEGFR2 antibody was pre-treated 30 min prior to the addition of Hsp20. β-actin was used as an internal control (n = 4; *, p<0.05 vs. Basal; #, p<0.05 vs. IgG+Hsp20).

Article Snippet: Samples or recombinant mouse Hsp20 protein (EIAab Science) were added and incubated for 2 h followed by three washes in PBST.

Techniques: Recombinant, Expressing, Migration, Control, Western Blot

(A) Blood vessels were stained for CD31 (capillary density) in heart sections of WT and Hsp20 TG mice, and (B) their quantitative analysis. For quantification of positively stained vessels, five sections of each heart (n = 4 hearts per group) were analyzed by an investigator who was blinded with respect to samples. Blood vessels were detected at low magnification (×200). Images are representative sections from four mice per group (green, α-Actin; red, CD31). Scale bar, 50 µm.

Journal: PLoS ONE

Article Title: Hsp20 Functions as a Novel Cardiokine in Promoting Angiogenesis via Activation of VEGFR2

doi: 10.1371/journal.pone.0032765

Figure Lengend Snippet: (A) Blood vessels were stained for CD31 (capillary density) in heart sections of WT and Hsp20 TG mice, and (B) their quantitative analysis. For quantification of positively stained vessels, five sections of each heart (n = 4 hearts per group) were analyzed by an investigator who was blinded with respect to samples. Blood vessels were detected at low magnification (×200). Images are representative sections from four mice per group (green, α-Actin; red, CD31). Scale bar, 50 µm.

Article Snippet: Samples or recombinant mouse Hsp20 protein (EIAab Science) were added and incubated for 2 h followed by three washes in PBST.

Techniques: Staining

Intracellular Hsp20 is released outside cardiomyocytes via exosomes, and then interacts with VEGFR2. Consequently, its downstream signaling pathways (i.e. Akt and ERK) are activated, which promote myocardial angiogenesis.

Journal: PLoS ONE

Article Title: Hsp20 Functions as a Novel Cardiokine in Promoting Angiogenesis via Activation of VEGFR2

doi: 10.1371/journal.pone.0032765

Figure Lengend Snippet: Intracellular Hsp20 is released outside cardiomyocytes via exosomes, and then interacts with VEGFR2. Consequently, its downstream signaling pathways (i.e. Akt and ERK) are activated, which promote myocardial angiogenesis.

Article Snippet: Samples or recombinant mouse Hsp20 protein (EIAab Science) were added and incubated for 2 h followed by three washes in PBST.

Techniques: Protein-Protein interactions

PLY-EVs induce dendritic cell maturation and inflammatory cytokine release upon internalization (A) Confocal microscopy images showing the internalization of CFSE-labelled PLY (0.1) and naive EVs (green) by THP-1-monocyte-derived DCs at 24 h post-treatment. Scale bars, 25 μm. (B) Flow cytometry histograms ( N = 3) to quantify the DC uptake of CFSE-labeled PLY(0.5)EVs and naive EVs. (C) Dose-dependent uptake of PLY (0.1, 0.5) EVs by DCs. (D) Phase-contrast microscopy images of immature day 5 DCs coincubated with PLY (0.1, 0.5) EVs and naive EVs for 24 h. Arrows indicate matured DCs (magnified in inset). Scale bars, 50 μm. Images are representative of three independent experiments. (E–G) Flow cytometry histograms ( N = 3) to quantify the expression levels of (E) CD80, (F) CD86, and (G) CD83 on THP-1-monocyte-derived DCs treated with PLY(0.5) and naive EVs. (H and I) Flow cytometry histograms ( N = 2) showing the expression levels of DC maturation marker CD83 at 96 h post-incubation of primary human monocytes with (H) PLY(0.5) and naive EVs and (I) naive EVs pre-treated with recombinant PLY protein (naive EVs+rPLY). (J and K) Cytokine ELISA showing the levels of secreted TNF-α from (J) DCs treated with PLY (0.1) EVs or naive EVs alone ( N = 3) for 24 h and (K) DCs pre-treated with PLY (0.1,0.5) or naive EVs for 24 h followed by subsequent infection with S. pneumoniae , T4R strain ( N = 2). Recombinant PLY (0.5 μg/mL) was used as positive control. All data are represented as mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.005, and ∗∗∗ p < 0.001 by one-way ANOVA with Tukey’s multiple comparisons test. n.s., not significant. See also <xref ref-type=Figures S6–S9 . " width="100%" height="100%">

Journal: iScience

Article Title: Bacterial pore-forming toxin pneumolysin drives pathogenicity through host extracellular vesicles released during infection

doi: 10.1016/j.isci.2024.110589

Figure Lengend Snippet: PLY-EVs induce dendritic cell maturation and inflammatory cytokine release upon internalization (A) Confocal microscopy images showing the internalization of CFSE-labelled PLY (0.1) and naive EVs (green) by THP-1-monocyte-derived DCs at 24 h post-treatment. Scale bars, 25 μm. (B) Flow cytometry histograms ( N = 3) to quantify the DC uptake of CFSE-labeled PLY(0.5)EVs and naive EVs. (C) Dose-dependent uptake of PLY (0.1, 0.5) EVs by DCs. (D) Phase-contrast microscopy images of immature day 5 DCs coincubated with PLY (0.1, 0.5) EVs and naive EVs for 24 h. Arrows indicate matured DCs (magnified in inset). Scale bars, 50 μm. Images are representative of three independent experiments. (E–G) Flow cytometry histograms ( N = 3) to quantify the expression levels of (E) CD80, (F) CD86, and (G) CD83 on THP-1-monocyte-derived DCs treated with PLY(0.5) and naive EVs. (H and I) Flow cytometry histograms ( N = 2) showing the expression levels of DC maturation marker CD83 at 96 h post-incubation of primary human monocytes with (H) PLY(0.5) and naive EVs and (I) naive EVs pre-treated with recombinant PLY protein (naive EVs+rPLY). (J and K) Cytokine ELISA showing the levels of secreted TNF-α from (J) DCs treated with PLY (0.1) EVs or naive EVs alone ( N = 3) for 24 h and (K) DCs pre-treated with PLY (0.1,0.5) or naive EVs for 24 h followed by subsequent infection with S. pneumoniae , T4R strain ( N = 2). Recombinant PLY (0.5 μg/mL) was used as positive control. All data are represented as mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.005, and ∗∗∗ p < 0.001 by one-way ANOVA with Tukey’s multiple comparisons test. n.s., not significant. See also Figures S6–S9 .

Article Snippet: Mouse TNF-α DuoSet ELISA kit , R & D Systems , DY410-05.

Techniques: Confocal Microscopy, Derivative Assay, Flow Cytometry, Labeling, Microscopy, Expressing, Marker, Incubation, Recombinant, Enzyme-linked Immunosorbent Assay, Infection, Positive Control

Adoptive transfer of EVs from infected mice drives inflammation and pathology in a PLY-dependent manner (A) C57BL/6 mice were intranasally administered with 4 × 10 6 CFU of serotype 4 strain, T4 or the isogenic PLY mutant strain, T4Δply. At day 4 post-infection, EVs isolated from BALF were labeled and administered to healthy recipient mice at 35 μg/mice. The EV retention in murine respiratory tract was imaged by IVIS imaging and immune infiltration into lungs, and cytokine levels in BALF was measured. (B) Bacterial load in murine BALF ( N = 5 mice/group) upon infection with T4 and T4Δply strains was measured by CFU dilution assay. ∗∗ in (B) indicates p < 0.01 by Mann-Whitney test. (C) Quantification of relative total EV protein content from mice ( N = 3 mice/group) infected with T4 and T4Δply strains by BCA protein assay. PBS-treated mice served as control. ∗ and ∗∗ in (C) indicates p < 0.05 and p < 0.005, respectively, by unpaired t test. (D) IVIS imaging of mice intranasally administered with Nile-red-labeled EVs isolated from mice infected with T4 (EVs-T4) or T4Δply (EVs-T4Δply). EVs from PBS-treated mice (naive EVs) served as control. ROI intensity values indicate the total flux (photons/sec) recorded from the given region showing higher intensity of EVs from T4-infected mice in the respiratory tract. The color scale (photons/sec/cm 2 ) indicates the relative intensities of individual signals. (E and F) Flow cytometry analysis of inflammatory macrophages (F4/80 + ) and neutrophils (Ly6G + ) in BALF of mice ( N = 6 mice/group) administered with EVs from infected or untreated mice at 18 h. (G) TNF-α levels in the BALF of mice ( N = 5 mice/group) treated with EVs isolated from infected or untreated mice were measured post-sacrifice at 18 h by ELISA. ∗∗ and ∗∗∗ in (G) indicates p < 0.01 and p < 0.001, respectively, by unpaired t test. (H) Hematoxylin and eosin (H&E) staining of mouse lungs ( N = 6 mice/group) at 18 h post-administration of EVs from infected or PBS-treated mice. Mice treated with EVs from T4-infected mice showed tissue microlesions (MLEs) and immune cell infiltration in the alveolar interstitium indicative of PLY-induced tissue damage (magnified in the inset). BR, bronchiole; MLE, microlesions. Scale bars, 200 μm. Blind histopathological scoring was performed based on presence or absence of cellularity in alveolar interstitium and lesions. A score of “0” was given when no lesions were found, and a score of “1” was given to tissue showing increasing cellularity and lesions. Mouse BALF flow cytometry and histology data are representative of three independent experiments. All data are represented as mean ± SEM. See also <xref ref-type=Figure S12 . " width="100%" height="100%">

Journal: iScience

Article Title: Bacterial pore-forming toxin pneumolysin drives pathogenicity through host extracellular vesicles released during infection

doi: 10.1016/j.isci.2024.110589

Figure Lengend Snippet: Adoptive transfer of EVs from infected mice drives inflammation and pathology in a PLY-dependent manner (A) C57BL/6 mice were intranasally administered with 4 × 10 6 CFU of serotype 4 strain, T4 or the isogenic PLY mutant strain, T4Δply. At day 4 post-infection, EVs isolated from BALF were labeled and administered to healthy recipient mice at 35 μg/mice. The EV retention in murine respiratory tract was imaged by IVIS imaging and immune infiltration into lungs, and cytokine levels in BALF was measured. (B) Bacterial load in murine BALF ( N = 5 mice/group) upon infection with T4 and T4Δply strains was measured by CFU dilution assay. ∗∗ in (B) indicates p < 0.01 by Mann-Whitney test. (C) Quantification of relative total EV protein content from mice ( N = 3 mice/group) infected with T4 and T4Δply strains by BCA protein assay. PBS-treated mice served as control. ∗ and ∗∗ in (C) indicates p < 0.05 and p < 0.005, respectively, by unpaired t test. (D) IVIS imaging of mice intranasally administered with Nile-red-labeled EVs isolated from mice infected with T4 (EVs-T4) or T4Δply (EVs-T4Δply). EVs from PBS-treated mice (naive EVs) served as control. ROI intensity values indicate the total flux (photons/sec) recorded from the given region showing higher intensity of EVs from T4-infected mice in the respiratory tract. The color scale (photons/sec/cm 2 ) indicates the relative intensities of individual signals. (E and F) Flow cytometry analysis of inflammatory macrophages (F4/80 + ) and neutrophils (Ly6G + ) in BALF of mice ( N = 6 mice/group) administered with EVs from infected or untreated mice at 18 h. (G) TNF-α levels in the BALF of mice ( N = 5 mice/group) treated with EVs isolated from infected or untreated mice were measured post-sacrifice at 18 h by ELISA. ∗∗ and ∗∗∗ in (G) indicates p < 0.01 and p < 0.001, respectively, by unpaired t test. (H) Hematoxylin and eosin (H&E) staining of mouse lungs ( N = 6 mice/group) at 18 h post-administration of EVs from infected or PBS-treated mice. Mice treated with EVs from T4-infected mice showed tissue microlesions (MLEs) and immune cell infiltration in the alveolar interstitium indicative of PLY-induced tissue damage (magnified in the inset). BR, bronchiole; MLE, microlesions. Scale bars, 200 μm. Blind histopathological scoring was performed based on presence or absence of cellularity in alveolar interstitium and lesions. A score of “0” was given when no lesions were found, and a score of “1” was given to tissue showing increasing cellularity and lesions. Mouse BALF flow cytometry and histology data are representative of three independent experiments. All data are represented as mean ± SEM. See also Figure S12 .

Article Snippet: Mouse TNF-α DuoSet ELISA kit , R & D Systems , DY410-05.

Techniques: Adoptive Transfer Assay, Infection, Mutagenesis, Isolation, Labeling, Imaging, Dilution Assay, MANN-WHITNEY, Bicinchoninic Acid Protein Assay, Control, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Staining

Journal: iScience

Article Title: Bacterial pore-forming toxin pneumolysin drives pathogenicity through host extracellular vesicles released during infection

doi: 10.1016/j.isci.2024.110589

Figure Lengend Snippet:

Article Snippet: Mouse TNF-α DuoSet ELISA kit , R & D Systems , DY410-05.

Techniques: Virus, Mutagenesis, Isolation, Recombinant, Modification, Saline, Labeling, Staining, Electron Microscopy, Lysis, Western Blot, Buffer Exchange, Bicinchoninic Acid Protein Assay, Enzyme-linked Immunosorbent Assay, Clone Assay, Software, Membrane

κ ( A ) Immunoblotting of A20 and NF-κB p65 in whole-cell extract from B cell lymphoma cell lines. ( B ) Immunoblotting of NF-κB p65 in cytosolic and nuclear fractions of indicated cell lines. TBP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as loading controls. ( C ) Quantification of mean (±SD) TNF secretion by indicated cell lines ( n = 3 to 4 biological replicates). ( D ) Mean (±SD) proliferation and ( E ) viability of indicated cell lines ( n = 6 biological replicates) after 72 hours of incubation with anti-TNF antibody infliximab or human IgG (Intratect). Dotted lines represent seeded cell number. ( F ) Immunoblotting of A20 and NF-κB p65 after lentiviral transduction of A20 in RI-1 cells. ( G ) Immunoblotting of NF-κB p65 in cytosolic and nuclear fractions after A20 reconstitution in RI-1 cells. ( H ) Mean (±SD) TNF secretion after lentiviral transduction of A20 in RI-1 cells ( n = 3 biological replicates). ( I ) Mean (±SD) proliferation of A20-overexpressing RI-1 cells in the presence of infliximab ( n = 4 biological replicates). Statistics: one-way ANOVA. ( J ) Volcano plot showing differential gene expression between RI-1 wt and RI-1 + pLeGO-A20 as determined by RNA-seq performed in duplicates. Genes were considered differentially expressed with an adjust P < 0.01 and log 2 fold change >1. ( K ) Top down-regulated signaling pathways in RI-1 + pLeGO-A20 cells. All adjusted P values <0.0001. ( L ) Immunoblotting of NF-κB p65 in whole-cell extract and quantification of secreted TNF after incubation with 100 μM PDTC for 1 hour ( n = 3 biological replicates). ( M ) Quantification of mean (±SD) TNF secretion after stimulation with 100 ng/ml recombinant TNF for 1 hour ( n = 3 biological replicates). * P < 0.05; ** P < 0.01.

Journal: Science Advances

Article Title: A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors

doi: 10.1126/sciadv.adl3975

Figure Lengend Snippet: κ ( A ) Immunoblotting of A20 and NF-κB p65 in whole-cell extract from B cell lymphoma cell lines. ( B ) Immunoblotting of NF-κB p65 in cytosolic and nuclear fractions of indicated cell lines. TBP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as loading controls. ( C ) Quantification of mean (±SD) TNF secretion by indicated cell lines ( n = 3 to 4 biological replicates). ( D ) Mean (±SD) proliferation and ( E ) viability of indicated cell lines ( n = 6 biological replicates) after 72 hours of incubation with anti-TNF antibody infliximab or human IgG (Intratect). Dotted lines represent seeded cell number. ( F ) Immunoblotting of A20 and NF-κB p65 after lentiviral transduction of A20 in RI-1 cells. ( G ) Immunoblotting of NF-κB p65 in cytosolic and nuclear fractions after A20 reconstitution in RI-1 cells. ( H ) Mean (±SD) TNF secretion after lentiviral transduction of A20 in RI-1 cells ( n = 3 biological replicates). ( I ) Mean (±SD) proliferation of A20-overexpressing RI-1 cells in the presence of infliximab ( n = 4 biological replicates). Statistics: one-way ANOVA. ( J ) Volcano plot showing differential gene expression between RI-1 wt and RI-1 + pLeGO-A20 as determined by RNA-seq performed in duplicates. Genes were considered differentially expressed with an adjust P < 0.01 and log 2 fold change >1. ( K ) Top down-regulated signaling pathways in RI-1 + pLeGO-A20 cells. All adjusted P values <0.0001. ( L ) Immunoblotting of NF-κB p65 in whole-cell extract and quantification of secreted TNF after incubation with 100 μM PDTC for 1 hour ( n = 3 biological replicates). ( M ) Quantification of mean (±SD) TNF secretion after stimulation with 100 ng/ml recombinant TNF for 1 hour ( n = 3 biological replicates). * P < 0.05; ** P < 0.01.

Article Snippet: For inhibition or activation of NF-κB, 2 × 10 6 cells were seeded in six-well plates and incubated with 100 μM PDTC ammonium (Selleckchem) or recombinant TNF (100 ng/ml, Sigma-Aldrich) for 1 hour.

Techniques: Western Blot, Incubation, Transduction, Gene Expression, RNA Sequencing, Protein-Protein interactions, Recombinant